J&J, Bayer fail at their second big attempt to spotlight a safe benefit for clot-buster Xarelto in VTE
J&J and Bayer have run into a major setback in their long-running quest to widen the market for their clot-busting drug Xarelto. Their second crack at finding a safe benefit for at-risk patients facing incidents of venous thromboembolism (VTE) — clots in the deep veins — flopped in a major study of more than 12,000 patients who enrolled in the Mariner trial.
And this one proved a nasty surprise.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
